Disc Medicine (IRON) EBIT (2020 - 2026)

Disc Medicine (IRON) has reported EBIT for 7 consecutive years, with -$65.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, EBIT fell 5.97% year-over-year to -$65.1 million; the TTM figure through Jun 2026 stood at -$269.3 million (down 59.55% YoY), while the FY2025 annual figure was -$236.0 million, down 81.95% from the prior year.
• EBIT improved to -$65.1 million in Q2 2026 per IRON's latest filing, from -$69.5 million in the prior quarter.
• Across five years, EBIT topped out at -$10.0 million in Q1 2022 and bottomed at -$69.5 million in Q1 2026.
• Historically, EBIT has averaged -$35.5 million across 5 years, with a median of -$31.2 million in 2024.
• On a YoY basis, EBIT climbed as much as 43.2% in 2022 and fell as far as 173.9% in 2022.
• Disc Medicine's EBIT stood at -$15.0 million in 2022, then sank by 97.82% to -$29.7 million in 2023, then fell by 16.28% to -$34.6 million in 2024, then slumped by 93.84% to -$67.0 million in 2025, then gained by 2.83% to -$65.1 million in 2026.
• Business Quant data shows IRON's EBIT at -$65.1 million in Q2 2026, -$69.5 million in Q1 2026, and -$67.0 million in Q4 2025.